A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results